Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Non-Current Debt: 2023-2024

Historic Non-Current Debt for Tonix Pharmaceuticals Holding (TNXP) over the last 1 years, with Dec 2024 value amounting to $4.7 million.

  • Tonix Pharmaceuticals Holding's Non-Current Debt fell 28.87% to $4.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.7 million, marking a year-over-year decrease of 28.87%. This contributed to the annual value of $4.7 million for FY2024, which is 28.87% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Non-Current Debt of $4.7 million as of Q4 2024, which was down 9.76% from $5.2 million recorded in Q3 2024.
  • Tonix Pharmaceuticals Holding's 5-year Non-Current Debt high stood at $6.6 million for Q4 2023, and its period low was $4.7 million during Q4 2024.
  • For the 2-year period, Tonix Pharmaceuticals Holding's Non-Current Debt averaged around $5.6 million, with its median value being $5.7 million (2024).
  • Data for Tonix Pharmaceuticals Holding's Non-Current Debt shows a maximum YoY dropped of 28.87% (in 2024) over the last 5 years.
  • Tonix Pharmaceuticals Holding's Non-Current Debt (Quarterly) stood at $6.6 million in 2023, then fell by 28.87% to $4.7 million in 2024.
  • Its Non-Current Debt was $4.7 million in Q4 2024, compared to $5.2 million in Q3 2024 and $5.7 million in Q2 2024.